Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Feasibility Study Investigating Circulating Tumor DNA for Treatment Decisions

NCT03750175 is registered in ClinicalTrials.gov with Karen-Lise Garm Spindler as lead sponsor.

NCT NCT03750175
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03750175 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer - Feasibility Study Investigating Circulating Tumor DNA for Treatment Decisions
Lead sponsor
Karen-Lise Garm Spindler
Phase
Observational
Overall status
Completed
Start date
June 1, 2018
Completion date
December 31, 2022
Enrollment
49 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

braf gene mutation, circulating tumor dna, colorectal cancer metastatic, epidermal growth factor receptor inhibitor, kras gene mutation, nras gene mutation